Valproic acid sodium salt

SKU: orb1308057

Description

Valproic acid sodium salt

Research Area

Cell Biology, Epigenetics & Chromatin, Infectious Disease & Virology, Metabolism Research, Molecular Biology, Neuroscience, Pharmacology & Drug Discovery, Protein Biochemistry, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1069-66-5
• MW: 166.2
• Purity: 98.43%
• Formula: C₈H₁₅NaO₂
• SMILES: [Na+].CCCC(CCC)C([O-])=O
• Target: HDAC,GABA Receptor,Endogenous Metabolite,Apoptosis,Mitophagy,Gamma-secretase,HIV Protease,Autophagy
• Solubility: DMSO:25 mg/mL (150.42 mM);H2O:16.6 mg/mL (99.88 mM)

Bioactivity

• Target IC50:
  HDAC:0.5-2 mM HDAC1:0.4 mM
• In Vivo:
  In cultured cells, Valproic acid induces histone deacetylation similarly to the histone deacetylase inhibitor Trichostatin A, and like Trichostatin A, activate the transcription of various exogenous and endogenous promoters. however, in the embryos of vertebrates, both Valproic acid and Trichostatin A exhibit teratogenic effects without activating transcription. Valproic acid directly inhibits histone deacetylases through distinct pathways, with an IC50 of 0.4 mM for HDAC1. It inhibits cell proliferation or survival in F9 and P19 teratocarcinoma cells, as indicated by a decrease in [3H]thymidine incorporation, and promotes peroxisome proliferation in the liver of rodents. At a concentration of 1 mM Valproic acid inhibit the release of Gal4 fused with N-COR, TR, or PPARδ in cells expressin the DNA binding domain o the glucocorticoid receptor an the li and-binding domain of PPARδ, along with a GR-controlled Reporter gene fusion. Valproic acid reduce the accumulation of acetylated histones and inhibits HDAC activity. furthermore , Valproic acid induces specific types of differentiation, characterized by decreased proliferation, morphological changes, accumulation o the transcription factor AP-2, and expression of marker genes, where AP-2 serves as a potential marker for neuronal or neuroepithelial-like differentiation in F9 teratocarcinoma cells.
• In Vitro:
  I the MT-450 rat mammary carcinoma model, Valproic acid exhibits a delayed effect o the growth of Primary tumors.
• Cell Research:
  Valproic acid is dissolved in DMSO. In brief, × 0^5 cells are seeded in 96-well microtiter plates for MTT assays. After exposure to the designated doses of Valproic acid fo the indicated times, MTT solution [20 mL: 2 mg mL in phosphate-buffered saline (PBS)] is added to each well o the 96-well plates the plates are additionally incubated for 3 h at 37℃. Medium is withdrawn fro the plates by pipetting and 200 mL DMSO is added to each well to solubiliz the formazan crystals the optical density is measured at 570 nM using a microplate reader.

Storage & Handling

• Storage: keep away from moisture | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

bipolar disorder, Autophagy, anticonvulsant, anticancer, Apoptosis, Endogenous Metabolite, degradation, Mitophagy, Mitochondrial Autophagy, migraine, inhibit, Notch1, Notch, GABAReceptor, GABA Receptor, GABAR, epilepsy, Inhibitor, HDAC, HDAC2, headaches, HDAC9, hepatic fat accumulation, Gammasecretase, Human immunodeficiency virus, Histone deacetylases, HIV, HIV Protease, HIVProtease, Sodium Valproate, small cell lung cancer, SCLC, proteasomal, Valproic acid, Valproic acid sodium, Valproic acid sodium salt

Compound Identifiers

PubChem CID

16760703